Norwegion immuno-oncology play Targovax has promoted Øystein Soug, previously the company’s Chief Financial Officer, to the role of Chief Executive Officer. He succeeds Gunnar Gårdemyr, who has stepped down.

Finnish-Swedish biomaterial expert Stora Enso has appointed Annica Bresky as Executive Vice President, Consumer Board division and member of the Group Leadership Team. Bresky joins from Iggesund Paperboard AB, part of the Swedish Holmen Group, where she held the position of President and CEO. 
Irish drug developer Icon plc has announced that, come March 2017, Steve Cutler will take over the leadership of the company. He succeeds Ciaran Murray, who will in turn transition to the role of Chairman of the Board. 
Miquel A. Pericàs has taken over as general director of the Barcelona Institute of Science and Technology (BIST). The chemical engineer has been holding the position of director of the Institute of Chemical Research of Catalonia since 2000. 
3P Biopharmaceuticals has hired Andrew Carver as its new Senior Head of Business Development. Carver joins 3P from UK-based CDMO Fujifilm Diosynth Biotechnology. 
After being leaderless for over a year, EffRx has a new CEO. In October, EffRx announced that Lorenzo Bosisio has taken over the company’s helm in July. 
Swiss oncology expert Nouscom has appointed Marina Udier Blagovic as its Chief Operating Officer. The position has been newly created to drive all aspects of business operations and business development.

Cambridge-based drug discovery company Crescendo Biologics Ltd has named Theodora Harold its Chief Financial Officer. She has held this position in several early stage and growing biotechs. 

Oslo-based Nordic Nanovector has elected Joanna Horobin to its board as Non-executive Board Director. She replaces Renee Tannenbaum who stepped down from the board for personal reasons.

German mRNA company Curevac AG has appointed Pierre Kemula as Chief Financial Officer. Kemula joins Curevac from medtech firm Pixium Vision, where he was also responsible for financial activities.